Abstract
Background: Chronic Obstructive pulmonary disease a systemic inflammatory disease, characterized by airway inflammation and progressive airflow limitation is an increasing cause of morbidity and mortality worldwide including India. C-reactive protein (CRP) is an acute phase reactant secreted by the liver in response to infection, inflammation or tissue damage.
Objectives: The aim of this study was to investigate serum levels of CRP in North Indian population and to study its correlation with disease severity.
Methods: This case control study was conducted on 145 healthy controls and 145 stable COPD patients at a tertiary care hospital in north India. CRP levels were measured in serum by ELISA kits.
Results: The present study showed that mean serum CRP levels was significantly higher in COPD group as compared to control group (p<0.0001)]and the levels increased with the increasing severity of the disease.
Conclusion: Our study confirms that C-reactive protein levels were higher in stable COPD patients as compared to controls and their levels increased with the increasing severity of the disease. Measuring CRP levels in combination with other biochemical markers can be helpful in monitoring disease outcome and management of disease.
References
Peter J Barnes. “COPD: Is there light at the end of tunnel”. Review current opinion in pharmacology.2004; 263-272.
Lokke, P Lange, H Scharling, P Fabricius and J Vestbo. Developing COPD: a 25 year follow up study of the general population.Thorax.2006; 61: 935-939.
Garcia-Rio F, Miravitlles M, Soriano JB, Muñoz L, Duran-Tauleria E, Sánchez G, Sobradillo V, Ancochea J. EPI-SCAN Steering Committee: Systemic inflammation in chronic obstructive pulmonary disease: a population-basedstudy. Respiratory Research. 2010; 11:63.
Gan W, Man S, Senthilselvan A, Sin D, Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta-analysis. Thorax. 2004; 59: 574-580.
Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest. 2003; 111: 1805-1812.
Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006; 61: 849–853.
Hurst JR, Donaldson GC, Perera WR, Wilkinson TMA, Bilello JA, Hagan GW: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 174:867-874.
Dahl, M, Vestbo, J, Lange, P, Bojesan SE, Hansen AT, Nordestgaard BG. C-reactive protein as a predictor of prognosis in COPD. Am J Respir Crit Care Med. 2007; 175:250-255.
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. Available from: http://goldcopd.org/
Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004, 350:1005–1012.
Agustí AG, Noguera A, Sauleda J, Sala E, Pons JXB: Systemic effects of chronic obstructive pulmonary disease.Eur Respir J 2003, 21:347-36.
Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M,Rabe KF,Della Pasqua OE. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol & Ther 2006, 19:189-199.
Takabatake N, Nakamura H, Abe S, Hino T, Saito H, Yuki H, Kato S,Tomoike H. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 159:1215-1219.
Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Vessey RS, Ceilli BR. C- reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006; 61:23-28.
Higashimoto Y, Yamagata Y, Taya S, Iwata T, Okada M, Ishiguchi T,Sato H, Itoh H. Systemic inflammation in chronic obstructive pulmonary disease and asthma: Similarities and differences. Respirology 2008, 13:128-133.
Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006; 61:17–22.
De Torres JP, Cordoba-Lanus E, López-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, Celli BR, Casanova C. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006; 27:902–907.
Silva RD, Gazzana BM, Knorst MM C-reactive protein levels in stable COPD patients: a case-control study: Int J Chron Obstruct Pulmon Dis. 2015; 10: 1719–1725.
Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I. Smoking and tumour necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond) 2010; 7:29.
Mannino DM, Ford ES, Redd SC. Obstructive and Restrictive lung disease and marker of inflammation: data from third national health and nutrition examination. Am J Med. 2003; 114:758-762.
Karadag F, Kirdar S, Karul AB, Ceylan E: The value of C-reactive proteinas a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med. 2008, 19(2):104–108.
Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic bstructive pulmonary disease. Circulation. 2003; 107:1514–1519.
Yang L, Zhou M, Smith M, Yang G, Peto R, Wang J, Boreham J, Hu Y, Chen Z. Body mass index and Chronic obstructive pulmonary disease-related mortality: A nationally representative prospective study of 220,000 men in China. Int J Epidemiol. 2010; 39:1027-36.
Leuzzi G, Galeone C, Taverna F, Suatoni, Morelli D, Pastorino U. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017; 26: 160070.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array